Skip to main content

Contineum Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

CTNM$10.30+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Incorporated by Reference · Filed Herewith
Exhibit Number · Description · Form · File No. · Exhibit · Filing Date
3.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-420013.104/09/2024
3.2Amended and Restated Bylaws of the Registrant.8-K001-420013.204/09/2024
4.1Form of Registrant’s Class A common stock certificate.S-1/A333-2780034.104/01/2024
4.2Amended and Restated Investors’ Rights Agreement, dated February 9, 2021, by and among the Registrant and the other parties thereto.S-1333-2780034.203/15/2024
4.3^Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of September 1, 2020.S-1333-2780034.303/15/2024
4.4Letter Agreement, dated as of July 9, 2021, by and among the Registrant, Baker Brothers Life Sciences, L.P. and 667, L.P.S-1333-2780034.403/15/2024
4.5Amended and Restated Registration Rights Agreement dated as of July 9, 2021, by and between the Registrant and Baker Bros. Advisors LP.S-1333-2780034.503/15/2024
10.1+Executive Severance Plan, dated May 24, 2024, and form of agreement thereunder.8-K001-4200110.105/31/2024
10.2+Offer Letter, dated May 28, 2024, by and between the Registrant and John Healy.X
10.3+Non-Employee Director Compensation Program, as amended.X
10.4+Form of Registrant’s Mutual Arbitration Agreement.8-K001-4200110.405/24/2024
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1*Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
32.2*Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.X
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase DocumentsX
104Cover Page Interactive Data File (embedded within the Inline XBRL document)X
  • Indicates management contract or compensatory plan.

^ Pursuant to Item 601(a)(5) of Regulation S-K, certain exhibits and schedules have been omitted. The Registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.

  • The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.